Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria

Japanese Journal of Pharmacology

Volumn 82, Issue 1, 2000, Pages 82-84

  Takahashi, Atsushi ^a   Onodera, Kenji ^a   Shinoda, Hisashi ^a   Mayanagi, Hideaki ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Bone resorption; Calvaria; Phenytoin

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; PHENYTOIN;

ANIMAL TISSUE; ARTICLE; CALVARIA; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG TISSUE LEVEL; IN VITRO STUDY; MOUSE; NEWBORN; NONHUMAN; OSTEOLYSIS; TISSUE CULTURE;

EID: 0033964065     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.82.82     Document Type: Article

References (10)

1. Tolman KG, Jubiz W, Sannella JJ, Madsen JA, Belsey RE, Goldsmith RS and Freston JW: Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 56, 45-51 (1975)
2. Richens A and Rowe DJF: Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 4, 73-76 (1970)
3. Kamali F, Ball DE, McLaughlin WS and Seymour RA: Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth. J Periodont Res 34, 145-153 (1999)
4. 3 in rats. Tohoku Univ Dent J 17, 84-91 (1998) (in Japanese with English abstract)
5. Kruse K: On the pathogenesis of anticonvulsant-drug-induced alterations of calcium metabolism. Eur J Pediatr 138, 202-205 (1982)
6. Nakaede O, Baylink DJ and William Lau KH: Phenytoin at micromolar concentrations is an osteogenic agent for human-mandible-deriverd bone cells in vitro. J Dent Res 74, 331-337 (1995)
7. 3. Calcif Tissue Int 35, 172-176 (1983)
8. Hahn TJ, Scharp CR, Richardson CA, Halstead LR, Kahn AJ and Teitelbaum SL: Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 62, 406-414 (1978)
9. Kutt H and McDowell F: Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients. JAMA 203, 969-972 (1968)
10. Välimäki MJ, Tihonen M, Laitinen K, Tahtela R, Karkkainen M, Lamberg-Allardt C, Makela P and Tunninen R: Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs. J Bone Miner Res 9, 631-637 (1994)